Pfizer (PFE) Long-Term Deferred Tax (2009 - 2026)

Pfizer (PFE) has reported Long-Term Deferred Tax for 18 consecutive years, with $10.8 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 4.17% year-over-year to $10.8 billion in Q2 2026; TTM through Jun 2026 was $10.8 billion, a 4.17% increase from a year earlier, with the FY2025 full-year figure at $9.7 billion, down 44.49% from the prior year.
• Long-Term Deferred Tax was $10.8 billion for Q2 2026 at Pfizer, up from $10.0 billion in the prior quarter.
• Over five years, Long-Term Deferred Tax peaked at $17.5 billion in Q4 2024 and troughed at $4.9 billion in Q1 2024.
• A 5-year average of $9.9 billion and a median of $9.6 billion in 2025 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax soared 159.91% in 2022 and plunged 44.49% in 2025, its largest moves.
• Over 5 years, Long-Term Deferred Tax stood at $13.3 billion in 2022, then soared by 30.41% to $17.3 billion in 2023, then increased by 1.01% to $17.5 billion in 2024, then sank by 44.49% to $9.7 billion in 2025, then grew by 11.08% to $10.8 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $10.8 billion (Q2 2026), $10.0 billion (Q1 2026), and $9.7 billion (Q4 2025), per Business Quant data.